1. Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. (3rd October 2022) Authors: Slama, M; Obici, L; Okumura, T; Arum, S; Hale, C; Jay, P Y; Capocelli, K; Gonzalez-Duarte, A Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. (25th November 2020) Authors: Gillmore, J; Berk, J; Dispenzieri, A; Polydefkis, M; Gonzalez-Duarte, A; Sekijima, Y; Sweetser, M.T; Arum, S; Wang, J.J; White, M.T; Maurer, M Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗